[b]Imo the order was planned out, 1st 8-K shows a very small debt load to be settled, followed by a Potential Multi Million Dollar contract, in other words debt will be taking care of easily and then followed by the 2nd 8-K showing the Appointment of a HUGE PLAYER....This is only the beginning Folks, Line Up at the ASK, no one selling here!

[/b]

[b]1ST 8-K >> Immunotech Laboratories, Inc.

[/b]

Pasadena, Calif.---- 2/ 4, 2013--- Immunotech Laboratories, Inc.

Like to inform the share holders for the unresolved debt of the company. Immunotech Laboratories,Inc. still has obligation of $ 1,550,000.00 to Zhabilov Trust in consideration of the Licensing agreement. Immunotech Laboratories ,Inc. still has obligation of $300,000.00 + in consideration of shell purchasing agreement. Presently Immunotech Laboratories, Inc. is in a state of insolvency to cover these expenses. The company continues working to settle these debts.

Further information can be obtained from www.immunotechlab.com

[b]HUGE PR >>

[/b]Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures

PASADENA, Calif., Feb. 4, 2013 /PRNewswire/ -- CSNNewswire/Immunotech Laboratories, Inc. (PINKSHEETS:IMMB)

Company Director Mr. Bo. Linton of Immunotech Laboratories, Inc, a Pasadena California based publicly traded company with patented "IPF" Technology today stated Immunotech's technology is now considered a major contender in the race for HIV & Cancer cures. Recent information provided by the company for clinical testing results in both the HIV and Cancer sectors for terminal (Salvage) patients showed the use of the company's patented "IPF" vaccine treatments significantly reduced the number of infected cells while leaving the non infected cells in tact, and almost immediately started the regeneration of the body's natural immune system.

Mr. Linton further commented the company recently received an initial inquiry for a significant order of the company's patented HIV vaccine by an International associate for use as an "Experimental Drug". If confirmed the initial order would be in excess of several Million Dollars. This would expand the company's operations from Research & Development to a Bio-Pharma manufacturing company. In Africa, where approved experimental treatments are permitted, there are approximately 30 Million HIV/AIDS patients alone.

[b]2ND 8-K >> Immunotech Laboratories, Inc.

[/b]

Pasadena, Calif.---- 2/ 4, 2013--- Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc. appoints Mr. Valentin Dimitrov to the board of directors of the company. Mr. Dimitrov is a CEO of M.T. Rose Corporation also Mr. Dimitrov is one of the owners of the second largest chemical plant in Bulgaria, Europe.

Further information can be obtained from www.immunotechlab.com